Results 21 to 30 of about 38,272 (314)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

BMC Pulmonary Medicine, 2022
Background Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), can reduce cardiovascular events and mortality in patients with heart failure. A number of mechanisms have been proposed to explain the beneficial effects of SGLT2
Yi Tang, Siyuan Tan, Minqi Li, Yijin Tang, Xiaoping Xu, Qinghai Zhang, Qinghua Fu, Mingxiang Tang, Jin He, Yi Zhang, Zhaofen Zheng, Jianqiang Peng, Tengteng Zhu, Wenlin Xie   +13 more
doaj   +1 more source

Targeting Autophagy, Apoptosis, and Oxidative Perturbations with Dapagliflozin Mitigates Cadmium-Induced Cognitive Dysfunction in Rats

Biomedicines, 2023
Cognitive decline and Alzheimer-like neuropathology are common manifestations of cadmium toxicity. Thanks to its antioxidant/anti-apoptotic features, dapagliflozin has demonstrated promising neuroprotective actions. However, its effect on cadmium-induced
Hany H. Arab, Ahmed H. Eid, Shuruq E. Alsufyani, Ahmed M. Ashour, Azza A. K. El-Sheikh, Hany W. Darwish, Fatma M. Sabry   +6 more
doaj   +1 more source

Meta‐analysis of the association between sodium‐glucose co‐transporter‐2 inhibitors and risk of skin cancer among patients with type 2 diabetes [PDF]

, 2018
A slight increase in melanoma risk was observed among sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitor users in the regular reports. However, the association remains uncertain.
Bailey, Barnett, Bode, Brockhaus, Cefalu, Chen, Deeks, DeFronzo, Ferrannini, Fralick, Grunberger, Haring, Higgins, Higgins, Häring, Jabbour, Kashiwagi, Kohler, Kovacs, Leiter, Lewin, Li, Nauck, Neal, Ridderstrale, Roden, Søfteland, Wanner, Yang, Zaccardi, Zinman   +30 more
core   +1 more source

Dapagliflozin protects against nonalcoholic steatohepatitis in db/db mice

Frontiers in Pharmacology, 2022
Nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease, is associated with type 2 diabetes mellitus and metabolic syndrome. Although there is no consensus on the treatment of NAFLD, growing evidence suggests that tight glycemic ...
Panshuang Qiao, Yingli Jia, Yingli Jia, Ang Ma, Jinzhao He, Chen Shao, Xiaowei Li, Shuyuan Wang, Baoxue Yang, Hong Zhou   +9 more
doaj   +1 more source

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study [PDF]

, 2018
Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of real-world studies comparing their effectiveness in routine clinical practice. Methods: This was a multicenter
Avogaro Angelo, Baldi, Ileana, Bossi, Antonio Carlo, Bottigliengo, Daniele, Cavalot, Franco, D'Angelo, Federica, DARWIN-T2D Network, Fadini, Gian Paolo, Morano S., Raffaella Buzzetti, Zatti, Giancarlo   +10 more
core   +1 more source

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.

Journal of the American Medical Association (JAMA), 2020
Importance Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.
M. Petrie, S. Verma, K. Docherty, S. Inzucchi, I. Anand, J. Bělohlávek, M. Böhm, C. Chiang, V. Chopra, Rudolf A. de Boer, Akshay S. Desai, M. Diez, J. Drożdż, A. Dukát, J. Ge, J. Howlett, T. Katova, M. Kitakaze, C. Ljungman, B. Merkely, J. Nicolau, E. O’Meara, P. N. Vinh, M. Schou, S. Tereshchenko, L. Køber, M. Kosiborod, A. Langkilde, F. Martinez, P. Ponikowski, M. Sabatine, M. Sjöstrand, S. Solomon, P. Johanson, P. Greasley, D. Boulton, O. Bengtsson, P. Jhund, J. McMurray   +38 more
semanticscholar   +1 more source

Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany. [PDF]

, 2016
OBJECTIVES: Dapagliflozin is an inhibitor of the human sodium-glucose co-transporter 2 (SGLT2) that has been shown to improve glycaemic control in patients with type 2 diabetes mellitus (T2DM).
Hammar, Niklas, Hankins, Matthew, Kim, Joseph, Tsai, Katherine   +3 more
core   +1 more source

Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes

Therapeutic Advances in Endocrinology and Metabolism, 2015
Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved as a treatment for type 2 diabetes mellitus (T2DM) in the United States, the European Union and other countries.
Deborah Hinnen
doaj   +1 more source

An emerging protagonist: Sodium Glucose Co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus [PDF]

, 2012
Contemporary therapies to rationalize the hyperglycaemia in type 2 diabetes mellitus (T2DM) generally involve insulin-dependent mechanisms and lose their effectiveness as pancreatic b-cell function decreases to a greater extent. The kidney emerges out as
Danish Ahmed, Manju Sharma, Pankaj S Yadav, Vikas Kumar   +3 more
core   +2 more sources

Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics

European Heart Journal, 2023
Background and Aims To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous ...
Su Ern Yeoh, J. Osmanska, M. Petrie, K. Brooksbank, A. Clark, K. Docherty, P. Foley, K. Guha, Crawford A. Halliday, P. Jhund, P. Kalra, Gemma McKinley, N. Lang, Matthew M. Y. Lee, A. McConnachie, J. McDermott, E. Platz, P. Sartipy, A. Seed, B. Stanley, R. Weir, P. Welsh, J. McMurray, R. Campbell   +23 more
semanticscholar   +1 more source